A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
The purpose of the study is to test 18F-BMS-986229 positron emission tomography (PET) imaging a practical and safe way to check the status of esophageal, stomach, and gastroesophageal junction cancer.
Esophagogastric Cancer|Esophagus Cancer|Esophageal Cancer|Gastric Cancer|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Gastroesophageal Junction Squamous Cell Carcinoma
DRUG: 18F-BMS-986229 Injection|DRUG: IV 18F-BMS-986229|DIAGNOSTIC_TEST: PET/CT Scan
Feasibility of 18F-BMS-986229 PET in participants with Gastroesophageal Cancer, 18F-BMS-986229 PET will be considered feasible if there are no Grade 3 or higher 18F-BMS-986229 related adverse events and if at least 7 to 10 participants in Cohort 1 (70%) are found to be 18F-BMS-986229 PET positive., 4 weeks
The purpose of the study is to test 18F-BMS-986229 positron emission tomography (PET) imaging a practical and safe way to check the status of esophageal, stomach, and gastroesophageal junction cancer.